CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Slightly Bullish +25

CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells ...

Gene editing Insider transaction AI-generated analysis

📉 General Counsel James Kasinger sold 10,400 shares of CRSP on September 22nd for a total value of $626,496.

📊 The insider sale represented a 9.89% reduction in his personal holdings, leaving him with approximately 94,784 shares.

💰 Following the transaction, Kasinger's remaining stake is valued at roughly $5.71 million based on current market prices.

📈 CRISPR Therapeutics stock opened at $55.70 and trades with a market cap of $5.39 billion.

💸 The company reported quarterly revenue of $10.18 million and an EPS loss of -$0.94 for the quarter ended June 30th.

📉 Analysts predict negative earnings of -$4.47 per share for the current fiscal year.

🏥 CRISPR Therapeutics' lead product, Casgevy (exa-cel), is approved in several markets for treating sickle cell disease and beta thalassemia.

🤝 The Casgevy therapy was developed in collaboration with Vertex Pharmaceuticals using CRISPR/Cas9 gene editing technology.

📊 Institutional investors own 69.20% of the company's outstanding shares.

📈 Hedge fund IFP Advisors Inc boosted its position by 29.9% in the 4th quarter, now holding 1,250 shares.

📈 Versant Capital Management Inc increased its holdings by 175.1% in the second quarter.

📈 D.A. Davidson & CO. grew its position by 5.9% in the first quarter.

📈 Kestra Advisory Services LLC expanded its stake by 2.0% in the first quarter.

🏦 Goldman Sachs maintains a 'neutral' rating with a $55.00 price target on CRSP shares.

🏦 UBS Group set an $80.00 price target on the stock in a recent research report.

🏦 Citigroup restated its rating to 'market outperform' on August 25th.

🏦 HC Wainwright reaffirmed a 'buy' rating on CRSP shares as of August 31st.

📊 The stock currently holds an average analyst rating of 'Moderate Buy' with a consensus price target of $67.94.

📉 Weiss Ratings issued a 'sell (d-)' rating on the company in July.

📉 The company has a negative return on equity of -24.39% and a negative net margin of -3,368.72%.

📈 CRSP has a beta of 1.76, indicating higher volatility than the broader market.

Bullish Signals
  • Institutional ownership remains strong at 69.20%, indicating continued confidence from major investors.
  • Several hedge funds increased their positions recently, with IFP Advisors Inc boosting holdings by 29.9% and Versant Capital Management Inc increasing stakes by 175.1%.
  • Major analysts maintain bullish or neutral stances, including HC Wainwright's 'buy' rating and Citigroup's 'market outperform' rating.
  • The consensus price target of $67.94 suggests potential upside from current trading levels.
  • Casgevy (exa-cel) is an approved gene-edited therapy for serious conditions like sickle cell disease, representing a significant commercial asset.
Risk Factors
  • General Counsel James Kasinger sold nearly 10% of his shares in a single transaction, which can signal insider caution.
  • Analysts predict continued negative earnings of -$4.47 for the current year, highlighting financial pressure.
  • Weiss Ratings issued a 'sell (d-)' rating, adding to mixed analyst sentiment regarding the stock's near-term prospects.
  • The company has a high beta of 1.76, exposing shareholders to significant market volatility.
Full Analysis
CRISPR Therapeutics AG (NASDAQ: CRSP) General Counsel James Kasinger sold 10,400 shares of the company's stock on September 22nd at an average price of $60.24 per share. The transaction totaled approximately $626,496 and resulted in a 9.89% decrease in his personal ownership, leaving him with 94,784 shares valued at roughly $5.71 million. This insider sale was disclosed via a document filed with the Securities & Exchange Commission. The company continues to trade with a market capitalization of $5.39 billion and a price-to-earnings ratio of -11.70, reflecting its pre-profit status in the biotechnology sector. Its stock has fluctuated between a one-year low of $44.12 and a high of $78.48, currently trading above its 50-day moving average of $53.63 but below its 200-day average of $52.75. Financially, CRISPR Therapeutics reported quarterly earnings of -$0.94 per share and revenue of $10.18 million for the quarter ended June 30th. Analyst consensus predicts negative earnings of -$4.47 for the current year. The stock holds a consensus price target of $67.94, with ratings ranging from 'Strong Buy' to 'Sell' among major investment banks. Institutional ownership remains significant at 69.20%, with several hedge funds increasing their positions in recent quarters. Key assets include Casgevy (exa-cel), a gene-edited cell therapy approved for sickle cell disease and beta thalassemia, developed in collaboration with Vertex Pharmaceuticals.